Clinical Trial Update: Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rigosertib to physician's choice in MDS patients after failure of hypomethylating agents was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome, MDS | Phase 3 | Status: TERMINATED